Edgestream Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Edgestream Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Sell	7,215 -4,369	-38%	-$1.03M	0.07%	483
2026 Q1	$2.31M	Sell	11,584 -11,305	-49%	-$2.24M	0.08%	460
2025 Q4	$4.33M	Buy	22,889 +11,962	+109%	+$2.3M	0.12%	301
2025 Q3	$1.94M	Buy	10,927 +7,162	+190%	+$1.06M	0.06%	537
2025 Q2	$428K	Buy	+3,765	New	+$402K	0.01%	752
2024 Q4	–	Sell	-34,069	Closed	-$3.41M	–	989
2024 Q3	$3.41M	Buy	+34,069	New	+$3.43M	0.15%	227
2022 Q2	–	Sell	-28,402	Closed	-$1.99M	–	578
2022 Q1	$1.99M	Sell	28,402 -14,073	-33%	-$1.02M	0.16%	214
2021 Q4	$4.09M	Sell	42,475 -11,129	-21%	-$1.03M	0.26%	119
2021 Q3	$4.66M	Sell	53,604 -14,969	-22%	-$1.16M	0.29%	114
2021 Q2	$5.61M	Buy	+68,573	New	+$5.7M	0.33%	101

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgestream Partners's LGND Position: Q2 2026 in Review

Edgestream Partners reduced its Ligand Pharmaceuticals (LGND) stake by 38% in Q2 2026, selling an estimated $1.03M and leaving 7,215 shares worth $2.28M. The position accounts for 0.07% of the portfolio, ranked #483.

Edgestream Partners first reported a position in LGND in Q2 2021 and has held it in 10 quarters since. The position peaked at $5.61M in Q2 2021. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Edgestream Partners held 7,215 shares of Ligand Pharmaceuticals worth $2.28M as of Q2 2026.
Edgestream Partners sold 4,369 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.03M.
Ligand Pharmaceuticals made up 0.07% of Edgestream Partners's portfolio in Q2 2026, its #483 holding.
Edgestream Partners first reported a position in Ligand Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
Edgestream Partners's Ligand Pharmaceuticals position peaked at $5.61M in Q2 2021.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.